14M Genomics–JW Communications: public relations, 201507 service existent by JW Communications |
2015-11-12 |
21st.BIO–Novo Group: investment, 202112 investment €86m by Novo Holdings |
2021-12-21 |
21st.BIO–Novozymes: industrial biotech production technology, 202112– co-excl license for technology platform from Novozymes |
2021-12-21 |
4BIO Ventures–SEVERAL: investment, 201909 first closing $50m of 4BIO Ventures II fund targeting $150m |
2019-09-09 |
4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms |
2023-06-01 |
4SC–HC Wainwright: investor conference, 201904 supply service 4SC presents at HC Wainwright Global Life Sciences Conference in London |
2019-04-07 |
4SC–Optimum Strategic Communications: public relations, 202309 service existent by Optimum |
2023-09-27 |
4titude–Brooks Automation: investment, 201710 acquisition $65m in cash of 4titude Ltd by Brooks |
2017-10-05 |
A-Mansia–Instinctif Partners: public relations, 201804 service existent by Instinctif |
2018-04-27 |
Aalto Bio Reagents–Biosynth Carbosynth: investment, 202205 acquisition of Aalto by Biosynth Carbosynth |
2022-05-25 |
AAX Biotech–Karolinska Institutet: investment, 202206 pre-seed investment of Karolinska Holdings AB |
2022-06-28 |
AB Science–Alpha Blue Ocean: investment, before 202106 investment by ABO |
2021-06-07 |
AbbVie–Mission Therapeutics: DUB inhibitors, 201811– collab RnD + license option €na for Alzheimer’s + Parkinson’s diseases |
2018-11-15 |
Abcam–BrickBio: antibody technology, 201911– collab use of BrickBio conjugation technology for research + diagnostic antibodies |
2019-11-08 |
Abcam–Danaher: investment, 202308– acquisition $24/share in cash = enterprise value $5.7b incl assumed indebtedness + net of acquired cash |
2023-08-28 |
Abcam–Instinctif Partners: public relations, 201807 service existent by Instinctif |
2018-07-02 |
Abcam–SEVERAL: investment, 202010 US IPO $156.5m+23.5m with 8.95m+1.34m ADSs at $17.5/ADS at Nasdaq Global Market |
2020-10-19 |
Abide Therapeutics–Lundbeck: investment, 201905 acquisition $250m upfront + $150m milestones of Abide by Lundbeck |
2019-05-06 |
Abingworth–Carlyle: investment, 202204–202208 acquisition €na of Abingworth by Carlyle |
2022-04-11 |
Abingworth–Goodwin Procter: legal services, 201807 supply service legal counsel for $315m Abingworth Bioventures VII Fund |
2018-07-09 |
Abingworth–Huntsworth: public relations, 202102 service existent by Citigate Dewe Rogerson |
2021-02-03 |
Abingworth–SEVERAL: investment, 201807 final closing of $315m Abingworth Bioventures VII Fund |
2018-07-09 |
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund |
2021-02-03 |
Abingworth–SEVERAL: investment, 202105 final closing at $582m of Abingworth Clinical Co-Development Fund 2 |
2021-05-10 |
Abivax–Kreos Capital: credit, 201807– debt financing up to €20m in 2 tranches with attached up to €1.6m warrants |
2018-07-25 |
Ablynx–Bank of America: investor conference, 201709 supply service Ablynx presents at BoAML Global Healthcare Conference London |
2017-09-15 |
Ablynx–JPMorgan Chase: investor conference, 201709 supply service Ablynx participates in JP Morgan’s London Small/Mid Cap Conference |
2017-09-14 |
Ablynx–Leucadia: investor conference, 201711 supply service Ablynx presents at Annual Jefferies Healthcare Conference London |
2017-12-16 |
Ablynx–Novo Group: investment, 201712– acquisition unsolicited cash offer €2.6b up to €30.5/share ANNOUNCED + REJECTED |
2017-12-22 |
ABP (NL)–Optimum Strategic Communications: public relations, 201811 service existent by Optimum for Inkef Capital |
2018-11-27 |
ABS Biotechnologies–OBN: investor conference, 202401 supply service ABS Biotechnologies presents at BioSeed 2024 London |
2024-01-22 |
Abzena–Alira Health: biologics discovery+ development services, 202202– collab launch DRIVE-Biologics services by Abzena + Alira Health + Oncodesign |
2022-02-24 |
Abzena–Biospring Partners: investment, 202007 investment $10m by Biospring Partners |
2020-07-28 |
Abzena–Biospring Partners: investment, 202203 financing round totalling $65m incl existing investor Biospring Partners |
2022-03-31 |
Abzena–Oncodesign: biologics discovery+ development services, 202202– collab launch DRIVE-Biologics services by Abzena + Alira Health + Oncodesign |
2022-02-24 |
Abzena–Ramarketing: public relations, 202202 service existent Ramarketing is press contact |
2022-02-24 |
Abzena–SEVERAL: investment, 202203 financing round $65m from majority owner WCAS with Biospring Partners + affilaited investors |
2022-03-31 |
Abzena–Welsh Carson Anderson & Stowe: investment, 201808– recommended cash offer 16p/share valueing Abzena at £34.4m by WCAS XII-Astra LP |
2018-08-16 |
Abzena–Welsh Carson Anderson & Stowe: investment, 202203 financing round totalling $65m incl majority owner WCAS |
2022-03-31 |
Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare |
2011-03-31 |
Acacia Pharma–Huntsworth: public relations, 201803 service existent by Citigate Dewe Rogerson |
2018-03-02 |
Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures |
2011-03-31 |
Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare |
2011-03-31 |
Acacia Pharma–SEVERAL: investment, 201802–201803 initial global offering €40m private placement 11.1m shares at €3.6 + listing on Euronext Brussels |
2018-02-05 |
Accession Therapeutics–Birk Venture: investment, 202109 seed financing round totalling £11m incl Birk Venture |
2021-09-20 |
Accession Therapeutics–Primavera Capital: investment, 202109 seed financing round totalling £11m incl Primavera Venture Partners |
2021-09-20 |
Accession Therapeutics–SEVERAL: investment, 202109 seed financing round £11m incl Primavera Venture Partners + Birk Venture |
2021-09-20 |
Accession Therapeutics–SEVERAL: investment, 202211 2nd financing round £16.6m incl iGlobe Partners + Primavera Venture Partners + Birk Venture |
2022-11-21 |
Achilles Therapeutics–Consilium: public relations, 202011 service existent by Consilium Strategic Communications |
2020-11-19 |
Achilles Therapeutics–Forbion: investment, 201909 financing round Series B totalling £100m incl new + co-investor Forbion |
2019-09-03 |
Achilles Therapeutics–Forbion: investment, 202011 financing round Series C totalling £52.7m incl existing investor Forbion |
2020-11-19 |
Achilles Therapeutics–Invus Group: investment, 201909 financing round Series B totalling £100m incl new + co-investor Invus |
2019-09-03 |
Achilles Therapeutics–Invus Group: investment, 202011 financing round Series C totalling £52.7m incl existing investor Invus |
2020-11-19 |
Achilles Therapeutics–OrbiMed: investment, 202011 financing round Series C totalling £52.7m incl new investor OrbiMed |
2020-11-19 |
Achilles Therapeutics–Perceptive Advisors: investment, 201909 financing round Series B totalling £100m incl new + co-investor Perceptive Advisors |
2019-09-03 |
Achilles Therapeutics–Perceptive Advisors: investment, 202011 financing round Series C totalling £52.7m incl existing investor Perceptive Advisors |
2020-11-19 |
Achilles Therapeutics–PNC Financial Services: public relations, 202011 service existent US investor relations by Solebury Trout |
2020-11-19 |
Achilles Therapeutics–RA Capital: investment, 201909 financing round Series B totalling £100m incl new + lead investor RA Capital Management |
2019-09-03 |
Achilles Therapeutics–RA Capital: investment, 202011 financing round Series C totalling £52.7m incl existing investor RA Capital Management |
2020-11-19 |
Achilles Therapeutics–Redmile Group: investment, 201909 financing round Series B totalling £100m incl new + co-investor Redmile Group |
2019-09-03 |
Achilles Therapeutics–Redmile Group: investment, 202011 financing round Series C totalling £52.7m incl existing investor Redmile Group |
2020-11-19 |
Achilles Therapeutics–SEVERAL: investment, 201909 financing round Series B £100m led by RA Capital Management |
2019-09-03 |
Achilles Therapeutics–SEVERAL: investment, 202011 financing round Series C £52.7m with new + existing investors |
2020-11-19 |
Achilles Therapeutics–SEVERAL: investment, 202103–202104 IPO $175.5m with 9.75m ADSs at $18/ADS at Nasdaq Global Select Market |
2021-03-01 |
Achilles Therapeutics–Syncona: investment, 201909 financing round Series B totalling £100m incl existing + co-investor Syncona |
2019-09-03 |
Achilles Therapeutics–Syncona: investment, 202011 financing round Series C totalling £52.7m incl existing investor Syncona |
2020-11-19 |
Achilles Therapeutics–Tavistock: investment, 202011 financing round Series C totalling £52.7m incl new investor Boxer Capital |
2020-11-19 |
Acousia Therapeutics–Instinctif Partners: public relations, 201805 service existent by Instinctif |
2018-05-14 |
Actimed Therapeutics–SEVERAL: investment, 201810 extended seed financing round Series A £1.25m from individual investors incl founders |
2018-10-31 |
Action Pharma–Abbott: AP214, 201205 acquisition $110m of AP214 by Abbott |
2012-05-01 |
Active Biotech–SEVERAL: investment, 202208– rights issue up to SEK54.5m with up to 54.5m new shares at SEK1/share |
2022-08-04 |
Adaptate Biotherapeutics–Abingworth: investment, 201910 investment by Abingworth + Takeda facilitating spin-out of Adaptate from GammaDelta Tx |
2019-10-16 |
Adaptate Biotherapeutics–SEVERAL: investment, 201910 spin-out from GammaDelta Therapeutics with investment from Abingworth & Takeda Pharmaceutical |
2019-10-16 |
Adaptate Biotherapeutics–Takeda: investment, 201910 investment by Abingworth + Takeda with time-limited option to acquire Adatpate for Takeda |
2019-10-16 |
Adaptate Biotherapeutics–Takeda: investment, 202201– acquisition existing investor Takeda exercises option to acquire Adaptate |
2022-01-10 |
Adaptimmune–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
Adaptimmune–Alpine Immune Sciences: cell therapy technology, 201905– collab + license to incorporte SIP + TIP technology into SPEAR T-cell therapies |
2019-05-15 |
Adaptimmune–Cowen: investor conference, 201703 supply service Adaptimmune presents at Cowen & Co Annual Health Care Conference 2017 |
2017-03-07 |
Adaptimmune–Deutsche Bank: investor conference, 201705 supply service Adaptimmune presents at Deutsche Bank Annual Health Care Conference |
2017-05-02 |
Adaptimmune–Hitachi: cell therapy manufacturing, 201801 existent manufacturing of SPEAR-T cells by PCT |
2018-01-05 |
Adaptimmune–Leucadia: investor conference, 201703 supply service Adaptimmune presents at Jefferies Immuno-Oncology Summit in Boston |
2017-03-30 |
Adaptimmune–Matrix Capital Management: investment, 201704 direct offering $42m of 7m ADSs at $6/ADS |
2017-04-05 |
Adaptimmune–Matrix Capital Manamagent: investment, 201809 registered direct offering totalling $100m incl existing investor Matrix Capital |
2018-09-05 |
Adaptimmune–New Enterprise Associates: investment, 201809 registered direct offering totalling $100m incl existing investor NEA 16 LP + NEA 14 LP |
2018-09-05 |
Adaptimmune–Noile-Immune: T cell therapy, 201908– collab up to $312m + royalties developm of SPEAR T-cell products using PRIME technology |
2019-08-27 |
Adaptimmune–SEVERAL: investment, 201703 public offering $60.06m+$5.88m net $61.8m with 14.3m+1.4m ADSs at $4.2/ADS |
2017-03-21 |
Adaptimmune–SEVERAL: investment, 201809 registered direct offering $100m of 10m ADSs at $10/ADS to Matrix Capital + NEA + Syncona |
2018-09-05 |
Adaptimmune–United Kingdom (govt): cell therapy manufacturing, 201801– dedicated vector mftg space at CGT Catapult Manufacturing Centre |
2018-01-05 |
Adaptimmune–Wellcome Trust: investment, 201809 registered direct offering totalling $100m incl new investor Syncona Portfolio Ltd |
2018-09-05 |
Adcendo–Gilde Investment: investment, 202104 financing round Series A totalling €51m incl co-investor Gilde Healthcare |
2021-04-29 |
Adcendo–Gilde Investment: investment, 202304 financing round Series A extension totalling €31m incl existing + co-investor Gilde Healthcare |
2023-04-04 |
Adcendo–Novo Group: investment, 202104 financing round Series A totalling €51m incl co-lead investor Novo Seeds |
2021-04-29 |
Adcendo–Novo Group: investment, 202304 financing round Series A extension totalling €31m incl existing + co-lead investor Novo Holdings |
2023-04-04 |
Adcendo–Odlander Fredrikson: investment, 202104 financing round Series A totalling €51m incl co-investor RA HealthCap |
2021-04-29 |
Adcendo–Odlander Fredrikson: investment, 202304 financing round Series A extension totalling €31m incl existing + co-investor HealthCap |
2023-04-04 |
Adcendo–Optimum Strategic Communications: public relations, 202104 service existent by Optimum |
2021-04-29 |
Adcendo–Pontifax: investment, 202304 financing round Series A extension totalling €31m incl new + co-lead investor Pontifax Venture Capital |
2023-04-04 |
Adcendo–RA Capital: investment, 202104 financing round Series A totalling €51m incl co-investor RA Capital Management |
2021-04-29 |
Adcendo–RA Capital: investment, 202304 financing round Series A extension totalling €31m incl existing + co-investor RA Capital Management |
2023-04-04 |
Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital |
2021-04-29 |